KROS vs TBRG
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
KROS presents a stark dichotomy between a perfect Piotroski F-Score (9/9) and collapsing fundamental growth. While the balance sheet is exceptionally strong with a current ratio of 15.45 and minimal debt, the company is experiencing a severe revenue contraction of -87.30% and extreme operating losses. The stock is significantly undervalued relative to its Graham Number ($28.33) and Intrinsic Value ($16.1), but this value is offset by bearish insider activity and a negative technical trend.
TBRG exhibits a strong operational turnaround indicated by a Piotroski F-Score of 7/9, yet it faces a severe valuation disconnect. While the current price of $23.18 trades at a massive premium to the Graham Number ($8.94) and Intrinsic Value ($2.03), the Forward P/E of 7.92 and PEG of 0.28 suggest the market is pricing in an aggressive earnings explosion. The company's pivot to Revenue Cycle Management (RCM) is yielding significant EPS surprises, but thin profit margins and market saturation in the small-hospital segment remain critical headwinds.
Compare Another Pair
Related Comparisons
KROS vs TBRG: Head-to-Head Comparison
This page compares Keros Therapeutics, Inc. (KROS) and TruBridge, Inc. (TBRG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.